Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3379

1.

B cell, CD8 + T cell and gamma delta T cell infiltration alters alveolar immune cell homeostasis in HIV-infected Malawian adults.

Mwale A, Hummel A, Mvaya L, Kamng'ona R, Chimbayo E, Phiri J, Malamba R, Kankwatira A, Mwandumba HC, Jambo KC.

Version 2. Wellcome Open Res. 2018 Apr 6 [revised 2018 Jan 1];2:105. doi: 10.12688/wellcomeopenres.12869.3. eCollection 2017.

2.

Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.

Natukunda E, Gaur AH, Kosalaraksa P, Batra J, Rakhmanina N, Porter D, Shao Y, Zhang H, Pikora C, Rhee MS.

Lancet Child Adolesc Health. 2017 Sep;1(1):27-34. doi: 10.1016/S2352-4642(17)30009-3. Epub 2017 Jun 29.

PMID:
30169223
3.

Structure-optimized dihydropyranoindole derivative GIBH-LRA002 potentially reactivated viral latency in primary CD4+ T lymphocytes of chronic HIV-1 patients.

Yang Q, Ding Y, Feng F, Pan E, Fan X, Ma X, Chen L, Zhao J, Sun C.

Medchemcomm. 2017 Jul 25;8(9):1806-1809. doi: 10.1039/c7md00327g. eCollection 2017 Sep 1.

4.

Association of Metabolic Syndrome and Oxidative DNA Damage in HIV/AIDS Patients.

Kolgiri V, Nagar V, Patil V.

Indian J Clin Biochem. 2018 Jul;33(3):273-281. doi: 10.1007/s12291-017-0670-5. Epub 2017 Jun 12.

PMID:
30072826
5.

Improving the solubility of nevirapine using A hydrotropy and mixed hydrotropy based solid dispersion approach.

Madan JR, Kamate VJ, Dua K, Awasthi R.

Polim Med. 2017 Jul-Dec;47(2):83-90. doi: 10.17219/pim/77093.

6.

A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DCSpecial Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)PLUS Meeting Abstract SummariesWith Expert Commentary by:Fred Poordad, MDChief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.

[No authors listed]

Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24. No abstract available.

7.

The substitution rate of HIV-1 subtypes: a genomic approach.

Patiño-Galindo JÁ, González-Candelas F.

Virus Evol. 2017 Oct 20;3(2):vex029. doi: 10.1093/ve/vex029. eCollection 2017 Jul.

8.

Cytotoxicity assessment, inflammatory properties, and cellular uptake of Neutraplex lipid-based nanoparticles in THP-1 monocyte-derived macrophages.

Berger E, Breznan D, Stals S, Jasinghe VJ, Gonçalves D, Girard D, Faucher S, Vincent R, Thierry AR, Lavigne C.

Nanobiomedicine (Rij). 2017 Dec 21;4:1849543517746259. doi: 10.1177/1849543517746259. eCollection 2017 Jan-Dec.

10.

[Neurosyphilis and HIV co-infection with the initial symptom of sudden deafness and optic atrophy: a case report].

Wang X, Ma RY, Yu Z, Li J, Zhang HF, Yu H.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Oct 5;31(19):1524-1525. doi: 10.13201/j.issn.1001-1781.2017.19.015. Chinese.

PMID:
29798109
11.

SURVEILLANCE OF HIV-1 DRUG-RESISTANCE MUTATIONS IN THAILAND FROM 1999 TO 2014.

Iemwimangsa N, Pasomsub E, Sukasem C, Chantratita W.

Southeast Asian J Trop Med Public Health. 2017 Mar;48(2):271-81.

PMID:
29641878
12.

Quionolone carboxylic acid derivatives as HIV-1 integrase inhibitors: Docking-based HQSAR and topomer CoMFA analyses.

Tong J, Zhan P, Wang XS, Wu Y.

J Chemom. 2017 Dec;31(12). pii: e2934. doi: 10.1002/cem.2934. Epub 2017 Aug 29.

13.

Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors: A Combinatorial Approach.

Valuev-Elliston VT, Kochetkov SN.

Biochemistry (Mosc). 2017 Dec;82(13):1716-1743. doi: 10.1134/S0006297917130107. Review.

14.

Impact of the Polymorphism rs9264942 near the HLA-C Gene on HIV-1 DNA Reservoirs in Asymptomatic Chronically Infected Patients Initiating Antiviral Therapy.

Herráiz-Nicuesa L, Hernández-Flórez DC, Valor L, García-Consuegra S, Navarro-Valdivieso JP, Fernández-Cruz E, Rodríguez-Sainz C.

J Immunol Res. 2017;2017:8689313. doi: 10.1155/2017/8689313. Epub 2017 Dec 28.

15.

Effect of Interleukin-28B polymorphism on Interleukin-28 expression and immunological recovery amongst HIV-1-infected individuals following antiretroviral therapy.

Srinidhi BV, Fletcher GJ, Sachidanantham J, Rupali P, Ramalingam VV, Demosthenes JP, Abraham OC, Pulimood SA, Rebekah G, Kannangai R.

Indian J Med Microbiol. 2017 Oct-Dec;35(4):580-584. doi: 10.4103/ijmm.IJMM_17_299.

16.

HCV genetics and genotypes dictate future antiviral strategies.

Papageorgiou L, Vlachakis C, Dragoumani K, Raftopoulou S, Brouzas D, Nicolaides NC, Chrousos GP, Charmandari E, Megalooikonomou V, Vlachakis D.

J Mol Biochem. 2017;6:33-40. Epub 2017 Dec 10.

17.

Plasma L-Carnitine and L-Lysine Concentrations in HIV-Infected Patients.

Butorov EV.

Open Biochem J. 2017 Dec 28;11:119-131. doi: 10.2174/1874091X01711010119. eCollection 2017.

18.

Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control.

Soper A, Kimura I, Nagaoka S, Konno Y, Yamamoto K, Koyanagi Y, Sato K.

Front Immunol. 2018 Jan 15;8:1823. doi: 10.3389/fimmu.2017.01823. eCollection 2017. Review.

19.

The Expanding Therapeutic Perspective of CCR5 Blockade.

Vangelista L, Vento S.

Front Immunol. 2018 Jan 12;8:1981. doi: 10.3389/fimmu.2017.01981. eCollection 2017. Review.

20.

Hepatitis B Virus Vaccination in HIV-1-Infected Young Adults: A Tool to Reduce the Size of HIV-1 Reservoirs?

Bekele Y, Graham RL, Soeria-Atmadja S, Nasi A, Zazzi M, Vicenti I, Naver L, Nilsson A, Chiodi F.

Front Immunol. 2018 Jan 10;8:1966. doi: 10.3389/fimmu.2017.01966. eCollection 2017.

Supplemental Content

Loading ...
Support Center